XML 41 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Sep. 30, 2017
Summary of Significant Accounting Policies  
Schedule of the Company's net sales by medical indication

(In thousands)

 

Three Months Ended
September 30,

 

Medical Indication

 

2017

 

2016

 

Antibiotic

 

$
3,349

 

$
3,780

 

Anti-Psychosis

 
14,991

 
17,320

 

Cardiovascular

 
11,306

 
12,694

 

Central Nervous System

 
8,818

 
10,350

 

Gallstone

 
6,564

 
12,883

 

Gastrointestinal

 
14,553

 
18,052

 

Glaucoma

 
2,668

 
5,783

 

Migraine

 
15,015

 
7,160

 

Muscle Relaxant

 
3,791

 
3,532

 

Pain Management

 
5,761

 
6,608

 

Respiratory

 
1,647

 
2,213

 

Thyroid Deficiency

 
47,214

 
39,838

 

Urinary

 
2,997

 
5,101

 

Other

 
12,696

 
11,182

 

Contract manufacturing revenue

 
3,591

 
5,063

 

 

 

 

 

 

 

Total

 

$
154,961

 

$
161,559

 

 

 

 

 

 

 

 

 

 

Summary of products which accounted for at least 10% of total net sales

 

 

2017

 

2016

 

 

 

 

 

 

 

Product 1

 
30

%
25

%

 

Summary of customers which accounted for at least 10% of total net sales

 

 

2017

 

2016

 

 

 

 

 

 

 

Customer A

 
27

%
28

%

Customer B

 
20

%
20

%